Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Sep 25, 2011
ESMO interviews Karim Fizazi, MD, PhD about the overall survival benefit of Radium-223 Chloride in the treatment of patients with symptomatic bone metastases in castration-resistant prostrate cancer - a Phase III randomized trial (ALSYMPCA). http://www.esmo.org
Video produced by the European Society for Medical Oncology (ESMO)